Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Valeant Continues Buying Spree With $2.6B Acquisition Of Medicis

This article was originally published in The Pink Sheet Daily

Executive Summary

The specialty pharma adds to its dermatology portfolio with a proposed acquisition of Scottsdale, Ariz.-based Medicis.

You may also be interested in...



Valeant’s Pearson Is Out, As Hunt Begins For A CEO To Right The Wrongs

Valeant has begun the search for a new CEO, who will be charged with turning around the troubled company and likely divesting some assets. The company also calls out former CFO Howard Schiller for “improper conduct.”

Nestle Grows Skin Care Footprint, Valeant Gains Antitrust Cover In Derma Deal

Swiss food and beverage firm Nestle grows its stake in North American skin care with its pending $1.4 billion acquisition from Valeant of five aesthetic dermatology brands, demonstrating its commitment to health and wellness, analysts say. Valeant resolves potential antitrust obstacles to its proposed Allergan acquisition.

Nestle Grows Skin Care Footprint, Valeant Gains Antitrust Cover In Derma Deal

Swiss food and beverage firm Nestle grows its stake in North American skin care with its pending $1.4 billion acquisition from Valeant of five aesthetic dermatology brands, demonstrating its commitment to health and wellness, analysts say. Valeant resolves potential antitrust obstacles to its proposed Allergan acquisition.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS074721

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel